Consumers have been urged to stop using a treadmill, after a series of incidents and one death. A shocking video released by the US Consumer Product Safety Commission (CPSC) shows a child getting dragged underneath a treadmill. Source: CPSC
Consumers have been urged to stop using a treadmill, after a series of incidents and one death. A shocking video released by the US Consumer Product Safety Commission (CPSC) shows a child getting dragged underneath a treadmill. Source: CPSC
Hyperion Metals Limited (ASX: HYM) ("Hyperion" or "the Company") is pleased to provide an update on the progress of the Company’s bulk test work and Phase 3 drilling program from its Titan critical mineral project ("Titan Project"), in Tennessee, USA.
American Tower Corporation (NYSE: AMT) today announced the pricing of its registered public offering of 9,000,000 shares of common stock at $244.75 per share. The offering was upsized from the previously announced offering size of 8,500,000 shares. The underwriters of the offering have an option to purchase up to an additional 900,000 shares of common stock to cover over-allotments, if any. The net proceeds of the offering are expected to be approximately $2,147.1 million (or approximately $2,361.8 million if the underwriters exercise their option to purchase additional shares in full) after deducting underwriting discounts and estimated offering expenses. American Tower expects to use the net proceeds from this offering, together with cash on hand and borrowings under its revolving credit facilities and term loans, to finance the recently announced Telxius transaction and to pay related fees and expenses. If for any reason the Telxius transaction is not completed, American Tower expects to use the net proceeds from these offerings to repay existing indebtedness and for general corporate purposes.
The COVID-19 crash was a dark moment for many investors. But for Hannah Rice, it triggered an overhaul in her thinking.
Former president threatens ‘corrupt social media companies’ will pay political price
World No.1 Ash Barty has again showed her class for a rival after her shock announcement. Find out what she said.
(Bloomberg) -- A bipartisan group of U.S. House lawmakers is asking the Biden administration to seek the elimination of Vietnam’s tariffs on American pork and address other restrictions as it engages with the Southeast Asian country over currency and trade practices.U.S. pork producers have failed to gain significant access to pork-loving Vietnam that has seen its domestic pig farms devastated by the African swine fever, increasing the demand for imported pork, according to a letter Wednesday to U.S. Trade Representative Katherine Tai that was signed by 72 members of Congress, both Republicans and Democrats,However, “significant tariff and non-tariff barriers unfortunately prevent U.S. pork from competing in that country, even as it seeks reliable sources of non-domestic pork,” the representatives said in the letter. “Consequently, our competitors in the EU as well as the Comprehensive and Progressive Trans-Pacific Partnership participants are well-positioned to take advantage of this tremendous opportunity given their free trade agreements with Vietnam.”Vietnam’s Ministry of Foreign Affairs did not immediately respond to an emailed request for comment made outside regular business hours.Vietnam has culled more than two million domestic pigs and imported hogs in the past two years because of African swine fever. Pork is the meat most Vietnamese rely on for daily protein.The representatives said in the letter to Tai that “the past few years have been extraordinarily difficult for U.S. pork producers due to trade retaliation from top U.S. export destinations” as well as disruptions brought about by the coronavirus pandemic.Vietnam last year temporarily cut its U.S. frozen pork import tariffs to 10% from 15%. This resulted in a doubling of American exports to the country during the second half of 2020 compared with the first six months of the year, the letter said. The temporary duty reduction expired at the end of 2020.U.S. producers also face restrictions to the Vietnamese market caused by “burdensome” administrative procedures, not recognizing the U.S. pork plant inspection and approval system and inconsistent processes for the import of some pork organ meat, said Maria Zieba, assistant vice president of international affairs for the National Pork Producers Council.(Updates with temporary tariff reduction in the seventh paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Quidel Corporation (NASDAQ: QDEL) ("Quidel"), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today a retail collaboration with Walgreens to make Quidel’s non-prescription QuickVue® At-Home OTC COVID-19 Test available to consumers at 7,600 Walgreens locations across the United States and Puerto Rico. The shelf-stable packages, each containing two of the self-administered rapid antigen tests, can also be ordered online at Walgreens.com for store pick-up or same day delivery.
Rafael Nadal has won the battle of new and old at the Madrid Open. Find out how the Spanish champion got it done.
Mexican President Andres Manuel Lopez Obrador on Wednesday rejected any link between his austerity drive and a metro line disaster that left 25 dead, as devastated families began to bury the victims.
Congresswoman says that GOP at ‘turning point’ over ex-president’s 2020 election lies
Players and staff from both AFL clubs in Sydney plus NRL side the Sydney Roosters are undergoing COVID-19 tests after a known case visited venues through the city's eastern suburbs.Sydney Roosters players were on Thursday morning rushed in for tests, some 36 hours out from Friday night's NRL clash with Parramatta.
The governor has said he will sign the bill, which is meant to address a shortage in lethal injection drugs
EXCLUSIVE: During her chat with Yahoo Lifestyle Beck claims the infamous clip was also 'edited for better TV'.
Out of all T-cell Leukemia pipeline therapies, HBI-8000 is set to capture the maximum patient pool owing to its immunomodulatory function.Los Angeles, USA, May 05, 2021 (GLOBE NEWSWIRE) -- T-cell Leukemia Pipeline: Comprehensive Analysis of 15+ Key Players and 15+ Key Therapies Out of all T-cell Leukemia pipeline therapies, HBI-8000 is set to capture the maximum patient pool owing to its immunomodulatory function. DelveInsight’s ‘T-cell Leukemia Pipeline Insights’ report provides a holistic view of the pipeline therapies that are under development in pre-clinical as well as clinical stages of development, and growth prospects across the T-cell Leukemia domain. Some of the key highlights of the T-cell Leukemia Pipeline report: T-cell Leukemia Pipeline report offers a comprehensive analysis of 15+ key players and 15+ key therapies.Out of all the emerging therapies, HBI-8000 is expected to capture the maximum patient pool owing to its immunomodulatory function. This oral agent targets class I histone deacetylase causing cell cycle arrest and tumor cell death as the mechanism underlying its single-agent activity against lymphoma.T-cell Leukemia pipeline comprises ASTX 660 (Otsuka Pharmaceutical) is in phase I/II while Valemetostat and Brentuximab vedotin (Seagen/Takeda) is in Phase II stage of development. HUYA Bioscience appears to have an upper edge as its therapy, HBI-8000 which is in the pre-registration phase. In April 2021, Shorla Pharma announced that the U.S. Food and Drug Administration (FDA) has accepted the filing application of its oncology drug SH-111 which is designed to treat T-cell Leukemia. Got queries? Want to know more? Request for Sample @ T-cell Leukemia Emerging Therapies and Forecast The report lays down a complete coverage of the therapeutics by development stage, product type, and route of administration, molecule type, and MOA type for T-cell Leukemia across the complete product development cycle, including all clinical and non-clinical stages. The T-cell Leukemia pipeline report puts on the table business opportunities, threats, prospective collaborations, strong competitors, growth strategies, and failed as well as discontinued drugs. T-cell Leukemia Pipeline Drugs DrugCompanyClinical PhaseMoARoAValemetostatDaiichi SankyoPhase IIHistone-lysine N-methyltransferase inhibitorsOralBNZ-1BionizPhase IIInterleukin receptor antagonistsIntravenousASTX 660Otsuka PharmaceuticalPhase I/IIInhibitor of apoptosis protein inhibitors; OralBrentuximab vedotinSeagen /TakedaPhase IIApoptosis stimulantsIntravenousHBI-8000HUYA BiosciencePreregistrationRas protein inhibitorsOral Request for Sample to know more @ T-cell Leukemia Pipeline Analysis, Key Companies and Futuristic Trends T-cell Leukemia Therapeutic Assessment The T-cell Leukemia Pipeline report proffers exhaustive insights into active pipeline assets segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Indications of various drugs. By Product Type MonoCombination By Stage Discovery Pre-clinicalINDPhase IPhase IIPhase IIIPre-registration By Molecule Type Small Molecule Gene TherapyStem Cell Therapy By Route of Administration IntravenousInhalationOralSubcutaneous By Mechanism of Action Enhancer of zeste homolog 1 and 2 protein inhibitorsHistone-lysine N-methyltransferase inhibitorsInterleukin 15 receptor antagonistsInterleukin 2 receptor antagonistsInterleukin 9 receptor antagonists1 Phosphatidylinositol 3 kinase inhibitors HDAC 1,2,3, and 10 protein inhibitorsMitogen-activated protein kinase inhibitors By Targets Protease Multiple Kinase Interleukin 15 receptorInterleukin 2 receptor Interleukin 9 receptorHistone-lysine N-methyltransferase Get in touch with our Business executive for Rich and Deep Market Assessment and Consulting Solutions Scope of the Report Coverage: GlobalKey Players: Daiichi Sankyo; Bioniz; Otsuka Pharmaceutical; Seagen /Takeda; HUYA Bioscience; iCell Gene Therapeutics; Gracell Biotechnology; Ascentage Pharma Group; Celgene Corporation; Shorla Pharma; AVM Biotechnology; Expression Therapeutics; miRagen Therapeutics, and others.Key T-cell Leukemia Pipeline Therapies: Valemetostat; BNZ-1; ASTX 660; Brentuximab vedotin; HBI-8000; CD4CAR; CD7 UCAR-T cells; APG-115; Romidepsin; SH-111; Cobomarsen; AVM-0703, and others. Reach out @ T-cell Leukemia Pipeline: Novel therapies and emerging technologies Table of Contents 1Introduction2Executive Summary3T-cell Leukemia Overview4T-cell Leukemia Pipeline Therapeutics5T-cell Leukemia Pipeline Therapeutic Assessment6T-cell Leukemia – DelveInsight’s Analytical Perspective7In-depth Commercial T-cell Leukemia Pipeline Assessment8T-cell Leukemia Collaboration Deals9Late Stage T-cell Leukemia Pipeline Products (Phase III and Preregistration)10Mid-Stage T-cell Leukemia Pipeline Products (Phase II)11Pre-clinical and Discovery Stage T-cell Leukemia Pipeline Products12Inactive T-cell Leukemia Pipeline Products13T-cell Leukemia Key Companies14T-cell Leukemia Key Products15T-cell Leukemia Unmet Needs16T-cell Leukemia Market Drivers and Barriers17T-cell Leukemia Future Perspectives and Conclusion18T-cell Leukemia Pipeline Analyst Views20Appendix Visit to know more of what’s covered @ T-cell Leukemia Emerging Therapies Browse through Related Reports CAR T-Cell Therapy for Acute Lymphoblastic LeukemiaDelveInsight’s “CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)- Market Insights and Market Forecast- 2030” report. CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline DelveInsight’s, “CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline landscape. Adult T Cell Leukemia Lymphoma MarketDelveInsight's "Adult T-Cell Leukemia-Lymphoma - Market Insights, Epidemiology, and Market Forecast-2030" report. Acute Myeloid Leukemia MarketDelveInsight's "Acute Myeloid Leukemia (AML) Market Insights, Epidemiology, and Market Forecast-2030" report. B-Cell Chronic Lymphocytic Leukemia MarketDelveInsight's "B-Cell Chronic Lymphocytic Leukemia - Market Insights, Epidemiology, and Market Forecast-2030" report. Hairy Cell Leukemia Market Insight Epidemiology and Market ForecastDelveInsight's 'Hairy Cell Leukemia (HCL)- Market Insights, Epidemiology and Market Forecast-2028' report. Bowens Disease MarketDelveInsight's "Bowen's Disease - Market Insights, Epidemiology, and Market Forecast-2030" report. Buergers Disease MarketDelveInsight's "Buerger’s Disease - Market Insights, Epidemiology, and Market Forecast-2030" report. Brucellosis MarketDelveInsight's "Brucellosis - Market Insights, Epidemiology, and Market Forecast-2030" report. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare, and Biotech News CONTACT: Shruti Thakur firstname.lastname@example.org +1(919)321-6187 www.delveinsight.com
MAFS bride Alana Lister is barely recognisable in several throwback photos taken before she had cosmetic surgery. See the surprising snaps here.
(Bloomberg) -- Indian drugmakers are warning that halting some cargo flights from China could disrupt the global drug supply chain. China supplies 60% to 70% of the raw materials used by Indian pharmaceutical firms as well as ingredients for finished medicines sent worldwide, according to Mahesh Doshi, national president for the Indian Drug Manufacturers’ Association.Moderna Inc. said mid-stage trials showed its booster shots were effective against strains of the coronavirus that emerged from Brazil and South Africa. Canada became the first nation to clear the Pfizer-BioNTech coronavirus vaccine for adolescents.The U.K. insisted a meeting of top Group of Seven diplomats in London should go ahead after India’s foreign minister said he would self-isolate over possible exposure to coronavirus. Meanwhile, new research suggests deaths from Covid-19 in India may double from current levels.Key DevelopmentsGlobal Tracker: Cases top 154.6 million; deaths exceed 3.23 millionVaccine Tracker: More than 1.21 billion doses have been givenModerna Covid booster shots prove effective against variants (Video)Vaccines work on this India variant. Experts fret about the nextHere comes the Covid-19 community corps and they want youWhat are vaccine passports and how would they work?: QuickTakeSubscribe to a daily update on the virus from Bloomberg’s Prognosis team here. Click CVID on the terminal for global data on cases and deaths.Thailand Steps Up Virus Stimulus Spending (8 a.m. HK)Thailand is planning to spend billions of dollars in providing financial relief to low-income groups to cope with the economic hit from the biggest Covid-19 outbreak sweeping the nation since the pandemic began.The cabinet gave in-principle approval on Wednesday for fiscal stimulus measures at a cost of 85.5 billion baht ($2.8 billion). It also proposed 140 billion baht worth of spending for co-payment and e-voucher programs and more cash handouts to welfare cardholders and special groups, officials said.Philippines Could Get 7 Million Doses in May (8 a.m. HK)The Philippines’ coronavirus inoculation drive could leap this month, with the possibility of increasing vaccine supplies to about 7 million shots from 4 million, which could lead to a further reopening of the economy.Kuala Lumpur Tightens Movement Restrictions (8 a.m. HK)Malaysia tightened restrictions on movements in the capital Kuala Lumpur to stem the rise in new Covid-18 infections, a day after imposing similar curbs in Selangor, its richest state.The movement control order, or MCO, will stay in force from May 7 to May 20, Defense Minister Ismail Sabri Yaakob said in a statement on Wednesday, adding the protocols already in place for other areas under MCO will apply.Case Cluster at Hanoi Hospital Grows (7:23 a.m. HK)Vietnam reported eight more infections linked to a cluster in the National Hospital for Tropical Diseases Campus of Dong Anh in Hanoi, taking the tally in the center to 22, the health ministry’s newspaper Suc Khoe Doi Song reported.The nation has reported 3,030 virus infections, including 64 local cases from April 27 when the country confirmed the first domestic patient in a month, and 35 deaths as of May 6 morning, the newspaper reported.Vietnam has ordered a strict border control and mandatory quarantines of three weeks while imposing some movement restrictions as it traces the recent flare up in coronavirus cases to overseas travelers.China Flight Halt May Snarl Supplies (6:50 a.m. HK)Drugmakers in India warn that a halt on some cargo flights from China could imperil an important link in the global pharmaceutical supply chain.The U.S. relies heavily on India to stock its medicine cabinets, and any slowdown in output could leave pharmacies short of drugs used regularly by millions of Americans.On April 26, China’s state-run Sichuan Airlines suspended cargo flights to India for 15 days amid an alarming second Covid-19 outbreak there. If the flights remain on hold, the drug industry fears “cascading effects on its entire supply chain,” Mahesh Doshi, national president for the Indian Drug Manufacturers’ Association, wrote in an April 29 letter to India’s external affairs minister.Argentina Has Record Number of Daily Deaths (6:45 a.m. HK)Argentina reported a record 663 deaths in the last 24 hours for a total of 65,865, according to the country’s evening report.There were 24,079 new Covid-19 cases reported, bringing the total to 3,071,496.Novavax Shows Efficacy Against Variant (5:41 p.m. NY)Novavax said initial primary analysis of Phase 2B results for its vaccine showed efficacy against a South African variant of the coronavirus.Among healthy adults without HIV, the Novavax vaccine showed efficacy of 60% in the initial analysis and 55% in the subsequent complete analysis, the company said.Novavax may have lost the race on vaccinating millions of Americans but a successful trial can still help developing nations like India and Brazil where shots are in high demand.Canada May Mix Vaccines Amid Supply Crunch (4:47 p.m. NY)Canada is considering allowing patients to receive two different types of vaccines as the country deals with shortages of shots from AstraZeneca Plc and Moderna Inc.Federal health officials are closely watching a U.K.-based trial in which participants received two kinds of shots. Results are expected in the next month or so, said Supriya Sharma, chief medical adviser at Health Canada.If adopted, the new protocol would mark another major deviation from original vaccine guidelines. Canada has opted to extend the length of time between mRNA vaccines from the recommended three to four weeks to as long as four months, in order to stretch supplies.Colorado Woman Pro-Vaccine Despite Clot (4:43 p.m. NY)A Colorado woman who suffered a rare blood clot after receiving Johnson & Johnson’s vaccine urged others to get a shot just the same.Morgan Wolfe, 40, of Denver, told the Colorado Sun: “Despite everything that’s happened, I definitely still think that it’s important to keep on pushing for as much of the country and as much of the world to get vaccinated as possible”“Obviously, I had a bad reaction to this one. And that’s unfortunate for me, but I do still think that there’s a place for it in the overall strategy,” Wolfe said.Moderna Booster Effective on Variants (4:08 p.m. NY)Moderna Inc.’s booster shots gave positive results against immune system-evading strains that emerged in South Africa and Brazil, according to early results from a mid-stage trial.Two types of booster shots studied spurred higher levels of virus-halting antibodies, Moderna said in a statement. One of the boosters is an additional low-dose shot of its existing vaccine, while the other type is customized against the South Africa strain.“We are encouraged by these new data, which reinforce our confidence that our booster strategy should be protective against these newly detected variants,” Stephane Bancel, Moderna’s chief executive officer, said in a statement. “We will continue to make as many updates to our Covid-19 vaccine as necessary to control the pandemic.”U.S. to Back Waiver of Vaccine IP Protections (3:25 p.m. NY)The U.S. will back a proposal to waive intellectual-property protections for Covid-19 vaccines, joining an effort to increase global supply and access to the life-saving shots as the gap between rich and poor nations widens.“We are for the waiver at the WTO, we are for what the proponents of the waiver are trying to accomplish, which is better access, more manufacturing capability, more shots in arms,” U.S. Trade Representative Katherine Tai said in an interview on Wednesday.The Biden administration will now actively take part in negotiations for the text of the waiver at the World Trade Organization and encourage other countries to back it, Tai said.She acknowledged the talks will take time and “will not be easy,” given the complexity of the issue and the fact that the Geneva-based WTO is a member-driven organization that can only make decisions based on consensus.Biden Touts Relief Funds for Restaurants (3 p.m. NY)President Joe Biden visited a Washington restaurant owned in part by Mexican immigrants on Wednesday to highlight $28.6 billion in federal aid for restaurants that struggled during the pandemic.Under the Covid-19 relief measure Biden signed in March, restaurants can apply for grants ranging from $1,000 to $5 million per location, or $10 million for those with 20 or fewer locations.Pandemic Delays FDA Plant Inspections (2:20 p.m. NY)Pandemic disruptions severely hampered U.S. regulators’ ability to inspect drug and device makers’ manufacturing plants, delaying at least 68 applications for approval to market new products, according to a Food and Drug Administration review.Seven of the delayed applications were mission-critical, meaning they represented a medical advancement, the agency said Wednesday in its report, and six of those were for new drugs. The delayed applications were among 600 where the FDA required a factory inspection before approval decisions.Yankees, Mets to Segregate Unvaccinated Fans (12:07 p.m. NY)New York Yankees and Mets stadiums will reopen to all fans on May 19, with separate sections for vaccinated and unvaccinated spectators.Those who are vaccinated can sit together at 100% capacity, as long as they wear masks. The unvaccinated fans will need to wear masks and also observe a 6-foot (1.8-meter) social distancing rule, which works out to about 33% capacity in those sections, Governor Andrew Cuomo said Wednesday.Fans will be able to get vaccines at the games, under a deal between the state and the teams. Those who get a shot at a game will get a free ticket to another game, Cuomo said. New York joins several other states offering incentives for vaccines as the pace of inoculations slow.The governor also announced that Broadway tickets will go on sale Thursday, with shows starting Sept. 14 at full capacity, Cuomo said.U.S. Cases Could See ‘Sharp Decline’: CDC (11:20 a.m. NY)U.S. Covid-19 cases could see a sharp decline by July if nationwide vaccination efforts continue to be successful, according to the Centers for Disease Control and Prevention.Researchers used scenario modeling techniques to show long-term projections of potential trends in Covid-19 cases, hospitalizations and deaths in data released Wednesday in the agency’s Morbidity and Mortality Weekly Report.Canada Clears Pfizer Shot for Teens (10:39 a.m. NY)Canadian public health officials authorized the use of the Pfizer Inc.-BioNTech SE Covid vaccine for teenagers, making Canada the first nation to do so. Supriya Sharma, chief medical adviser with Health Canada, made the announcement Wednesday at a press conference. The department determined the vaccine was “safe and effective” for the younger age group, Sharma said. The U.S. is considering similar action.G-7 Meeting Goes Ahead in U.K. (7:06 a.m. NY)The U.K. insisted a meeting of top Group of Seven diplomats in London should go ahead after India’s foreign minister Subrahmanyam Jaishankar said he would self-isolate over possible exposure to coronavirus.The news risked derailing a high-profile event that marked the G-7 debut of U.S. Secretary of State Antony Blinken. Britain is hosting the gathering, which began on Tuesday.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
The Pentagon said Wednesday it is following the trajectory of a Chinese rocket expected to make an uncontrolled entry into the atmosphere this weekend, with the risk of crashing down in an inhabited area.
(Bloomberg) -- Discover what’s driving the global economy and what it means for policy makers, businesses, investors and you with The New Economy Daily. Sign up hereBrazil’s central bank lifted its benchmark interest rate by 75 basis points and promised another hike of the same size next month in a renewed push to bring inflation back to target.The bank on Wednesday raised the Selic to 3.5%, in line with estimates from all economists in a Bloomberg survey and the guidance given by policy makers at their prior meeting in March. If it makes good on its promise, the bank will have raised borrowing costs by 225 basis points to 4.25% by June.“A partial normalization of the policy rate remains appropriate to keep some degree of monetary stimulus during the economic recovery,” central bank board members in wrote in a statement accompanying their decision. “However, the Committee emphasizes that there is no commitment with this plan, and that future steps of monetary policy could be adjusted to assure the achievement of the inflation target.”The bank, led by its President Roberto Campos Neto, is acting to rein in inflation that’s surged above the target ceiling to a four-year high. Food and fuel costs have jumped in recent months, and the government recently restarted emergency aid that will firm up demand. Put together, analysts see consumer prices above target this year and next despite an incipient recovery.What Bloomberg Economics Says“The central bank tried to reach a compromise: it promised another sharp rate hike of 75 basis points in the next meeting, but warned that it is not ready yet to fully normalize monetary policy. Despite acknowledging the decline in underlying inflation and mentioning -- for the first time ever -- its dual mandate, we believe that the overall tone of the statement was somewhat hawkish.”--Adriana Dupita, Latin America economistClick here for the full reportThe decision makes room for the real to extend recent gains. The Brazilian currency is the best performer among majors in the past month, up 4.4% amid rising commodity prices. A stronger exchange rate helps fight inflation by making imports less expensive.Real Has Scope to Gain After BCB’s Hiking Signal: Inside Brazil“They are continuing the hawkish tilt,” said Sacha Tihanyi, head of emerging market strategy at TD Securities in Toronto. “Hike aggressively sooner, and then create some breathing space for the real.”Nearing 8%For the first time, policy makers mentioned their secondary mandate of fostering full employment, introduced in the same law that gave the bank its long-sought formal autonomy earlier this year. Yet they offered a positive outlook, saying recent economic indicators have been better than expected despite the pandemic, and predicting uncertainties over growth to gradually return to normal.Last month, President Jair Bolsonaro’s administration started paying out another round of monthly stipends at a total cost of 44 billion reais ($8.2 billion). Lawmakers have recently indicated they will seek an extension of that aid if the government does not accelerate plans for a new social program as the coronavirus continues to spread through the country.Read More: Brazil’s Budget Foreshadows Another Year of Massive SpendingConsumer prices rose 6.17% in the year through mid-April, and many economists see that reading approaching 8% in May. The central bank targets annual inflation at 3.75% this year, with a tolerance range of plus or minus 1.5 percentage points.In their statement, policy makers wrote various measures of underlying inflation are already at the top of the range compatible with hitting their target. Complicating matters, commodity prices continue to increase, and higher energy costs are pressuring prices in the short-term.“The central bank is signaling it plans to get to a 5% Selic in 75-basis point hikes, though it leaves the space to change its mind,” said David Beker, chief Brazil economist at Bank of America Corp.(Updates with central bank statement in third paragraph, economist quote in fifth)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Tasmania's Labor opposition leader Rebecca White says she wants to continue in the job despite two election losses in the space of three years.The Liberal government appears on track to gain a 13th lower-house seat required for majority after Saturday's state poll, although final counting won't be completed until next week.
The federal government has vetoed a $370 million green energy project in far north Queensland despite its potential to deliver hundreds of jobs and cheaper energy.The Kaban Wind Farm and accompanying grid augmentation was expected to generate 250 jobs in the region and deliver more affordable power to households and businesses.